Shares of Jamieson Wellness Inc (TSE:JWEL) have received a consensus recommendation of “Buy” from the seven research firms that are covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have covered the stock in the last year is C$27.60.
Several equities analysts have issued reports on the company. Royal Bank of Canada raised their price objective on Jamieson Wellness from C$27.00 to C$29.00 and gave the stock an “outperform” rating in a report on Thursday, August 9th. National Bank Financial raised their price objective on Jamieson Wellness from C$25.25 to C$29.00 and gave the stock an “outperform” rating in a report on Tuesday, June 26th. Finally, TD Securities raised their price objective on Jamieson Wellness from C$27.00 to C$31.00 and gave the stock a “buy” rating in a report on Thursday, June 14th.
In other news, Director David Michael Williams acquired 10,000 shares of the company’s stock in a transaction on Monday, August 13th. The shares were bought at an average price of C$26.00 per share, with a total value of C$260,000.00.
About Jamieson Wellness
Jamieson Wellness Inc develops, manufactures, distributes, sells, and markets natural health products worldwide. The company operates in two segments, Jamieson Brands and Strategic Partners. The company offers health products for humans, including vitamins, herbals, and mineral nutritional supplements; and over-the-counter remedies under the Jamieson and LVHS brands, as well as sports nutrition products under the Progressive, Precision, and Iron Vegan brands.
Further Reading: What is Considered a Good Return on Equity (ROE)?
Receive News & Ratings for Jamieson Wellness Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jamieson Wellness and related companies with MarketBeat.com's FREE daily email newsletter.